FDA CLIA Waiver for FebriDx Unlocks Major Growth Opportunity for Atomo’s Pascal Platform

An update from Atomo Diagnostics Ltd. ( (AU:AT1) ) is now available.

Atomo Diagnostics stands out in the global rapid diagnostics sector with its patented Pascal cassette platform, which underpins a range of point-of-care and at-home tests targeting infectious diseases and early pregnancy. The company has built a portfolio of commercial supply agreements leveraging its integrated devices to improve ease of use and accuracy for both professional and untrained users.

The U.S. FDA’s CLIA waiver for Lumos Diagnostics’ FebriDx test, which is exclusively commercialised in Atomo’s Pascal cassette, dramatically expands FebriDx’s addressable market and unlocks significant upside for Atomo’s manufacturing business. Under an exclusive supply agreement running to June 2031, every FebriDx test supplied in the U.S. requires a Pascal cassette from Atomo, positioning the company to benefit from contracted minimum order revenues, volumes expected to far exceed those minimums, and growing demand as it scales Pascal production for Lumos and new pipeline customers.

The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.

More about Atomo Diagnostics Ltd.

Atomo Diagnostics Limited is an Australian-headquartered medical device company that supplies patented, integrated rapid diagnostic test devices to the global market. Its products are designed to simplify procedures and improve reliability for point-of-care and at-home testing, with commercialised applications in HIV, COVID-19, viral versus bacterial differentiation and early pregnancy detection.

Average Trading Volume: 1,633,680

Technical Sentiment Signal: Buy

Current Market Cap: A$32.41M

For a thorough assessment of AT1 stock, go to TipRanks’ Stock Analysis page.